Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage

References

• Powers AC. Diabetes Mellitus. In: Harrison’s Principles of Internal Medicine (16th Edition). Kasper DL, Fauci AS, Longa DL, Braunwald E, Hauser SL, Jameson JL (Eds). McGraw-Hill, OH, USA, 2152–2180 (2005).
   Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16, 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988–1994. Am. J. Prev. Med.22, 42–48 (2002).
   PubMed Web of Science ®Google Scholar
• Teuscher A, Egger M, Hermann JB. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. Arch. Intern. Med.149, 1942–1945 (1989).
   PubMedGoogle Scholar
• Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA276, 1886–1892 (1996).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology Guidelines Committee.2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Guidelines Sub-Committee. 1999 World Health Organization International Society of Hypertension guidelines for the management of hypertension. J. Hypertens.17, 151–183 (1999).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr. Hypertens. Reports4, 343–349 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever, PS, Poulter, NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs65(Suppl. 2), 1–10 (2005).
   PubMed Web of Science ®Google Scholar
• McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs64, 1923–1940 (2004).
   PubMed Web of Science ®Google Scholar
• Murakami K, Kimura G, Imanishi M et al. Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension. Blood Press.1(Suppl. 3), 114–118 (1992).
   Google Scholar
• Hayashi K, Ozawa Y, Fujiwara K et al. Role of actions of calcium antagonists on efferent arterioles – with special references to glomerular hypertension. Am. Nephrol.23, 229–244 (2003).
   PubMed Web of Science ®Google Scholar
• Takabatake T, Ohta H, Sasaki T et al. Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients. Eur. J. Clin. Pharmacol.45, 321–325 (1993).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin F, Rodriguez-Rosas H, Peiro-Martinez I et al. Relationship between sympathetic activation, pulse pressure and heart rate in hypertensive Type 2 diabetic patients with microalbuminuria, treated with manidipine vs amlodipine [abstract]. J. Hypertens.23(Suppl. 2), S376 (2005).
   Google Scholar
• Fogari R, Zoppi A, Corradi L et al. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J. Hypertens.18, 1871–1875 (2000).
   PubMed Web of Science ®Google Scholar
• Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am. J. Cardiol.75, 7F–12F (1995).
   PubMed Web of Science ®Google Scholar
• Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am. J. Hypertens.4(1 Pt 2), 23S–28S (1991).
   Google Scholar
• Rizzoni D, Bevilacqua M, Gobbato C et al. Blood pressure lowering effects of delapril and manidipine in hypertensive patients with Type 2 diabetes not adequately controlled by monotherapy. High. Blood. Press. Cardiovasc. Prev.12, 180 (2005).
   Google Scholar
• Mugellini A, Preti P, Zoppi A et al. Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with Type II diabetes mellitus. J. Hum. Hypertens.18, 687–691 (2004).
   PubMed Web of Science ®Google Scholar
• Mugellini A, Lazzari P, Zoppi A et al. Effect of delapril manidipine combination vs olmesartan hydrochlorothiazide combination on insulin sensitivity in obese hypertensive patients. J. Hypertens.24(Suppl. 4), S217 (2006).
   Google Scholar
• Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs61, 1777–1799 (2001).
   PubMed Web of Science ®Google Scholar
• Rossillon D, Stockis A, Poli G et al. Food effect on the oral bioavailability of manidipine: single dose, randomized, crossover study in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet.23, 197–202 (1998).
   PubMedGoogle Scholar
• Morimoto S, Matsumura Y. Manidipine hydrochloride [CV 4093 (2HCL)]. Cardiovasc. Drug Rev.9, 207–222 (1991).
   Google Scholar
• Deroubaix X, Lins R, Lens S et al. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls. Int. J. Clin. Pharmacol. Ther.36, 386–391 (1998).
   PubMed Web of Science ®Google Scholar
• Onoyama K, Nanishi F, Okuda S et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clin. Pharmacol. Ther.43, 242–249 (1988).
   PubMed Web of Science ®Google Scholar
• Stockis A, Gengler C, Goethals F. et al. Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers. Arzneimittelforschung53, 627–634 (2003).
   PubMed Web of Science ®Google Scholar
• Stockis A, De Bruyn S, Gengler C et al. Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects. Arzneimittelforschung53, 554–561 (2003).
   PubMed Web of Science ®Google Scholar
• Bacchelli S, Degli Esposti D, Alberici M et al. Effects of the combination of different doses of manidipine and delapril in hypertensive patients. Am. J. Hypertens.15(4 Pt 2), 45A–46A (2002).
   Google Scholar
• Ogihara T, Kaneko Y, Ikeda M et al. Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril. Am. J. Hypertens.4(1 Pt 2), 42S–45S (1991).
   PubMedGoogle Scholar
• Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am. J. Hypertens.13, 461–467 (2000).
   PubMed Web of Science ®Google Scholar
• Omboni S, Fogari R, Mancia G. A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives. Blood Press.10, 170–175 (2001).
   PubMed Web of Science ®Google Scholar
• Shiba T, Inoue M, Tada H et al. Delapril versus manidipine in hypertensive therapy to halt type-2-diabetes-mellitus-associated nephropathy. Diabetes Res. Clin. Pract.47, 97–104 (2000).
   PubMed Web of Science ®Google Scholar
• Zoppi A, Mugellini A, Preti P et al. Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a Phase III, multicenter, open-label, clinical trial. Curr. Ther. Res. Clin. Exp.64, 422–433 (2003).
   PubMed Web of Science ®Google Scholar
• Mugellini A, Vaccarella A, Celentano A et al. Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: Evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press.14(Suppl. 1), 6–13 (2005).
   PubMed Web of Science ®Google Scholar
• Mugellini A, Dobovisek J, Planinc D et al. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin. Ther.26, 1419–1426 (2004).
   PubMed Web of Science ®Google Scholar
• Karpati P, Alberici M, Tocci G et al. Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in patients with essential hypertension. High. Blood. Press. Cardiovasc. Prev.10, 81–86 (2003).
   Google Scholar
• Preti P, Destro M, Lazzari P et al. Efficacy and tolerability of delapril-manidipine combination vs olmesartan-hydrochlorothiazide fixed combinations in elderly diabetic hypertensive patients. American Society of Hypertension 21st Annual Meeting. NY, USA 16–20 May 2006 (Abstract P 219).
   Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med.329, 1456–1462 (1993).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol.16, 3027–37 (2005).
   PubMed Web of Science ®Google Scholar
• Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs65(Suppl. 2), 29–39 (2005).
   PubMed Web of Science ®Google Scholar
• Bellinghieri G, Mazzaglia , Savica V, Santoro, D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren. Fail.25, 681–689 (2003).
   PubMed Web of Science ®Google Scholar
• Del Vecchio L, Pozzi M, Salvetti A et al. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril. J. Nephrol.17, 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• Deerochanawong C, Kornthong P, Phongwiratchai S, Serirat S. Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive Type 2 diabetic patients with microalbuminuria. J. Med. Assoc. Thai.84, 234–241 (2001).
   PubMedGoogle Scholar
• Fogari R, Mugellini A, Zoppi A. et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur. J. Clin. Pharmacol.61, 483–490 (2005).
   PubMed Web of Science ®Google Scholar
• Kjeldsen S, Julius, S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzymes inhibitors and angiotensin receptor blockers. Am. Heart J.148, 747–754 (2004).
   PubMed Web of Science ®Google Scholar
• Schmieder R, Schlaich M, Klingbeil A et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol. Dial. Transplant.13, 564–569 (1998).
   PubMed Web of Science ®Google Scholar
• Folsom AR, Rosamond WD, Shahar E et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation100, 736–742 (1999).
   PubMed Web of Science ®Google Scholar
• Held C, Hjemdahl P, Hakan Wallen N et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis148, 179–188 (2000).
   PubMed Web of Science ®Google Scholar
• Fogari R, Malamani GD, Savino S et al. Effects of different dihydropyridine calcium antagonists on pretibial subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens.11(4 Pt 2), 114A (1998).
   Google Scholar
• Zanchetti A, Omboni S, La Commare P et al. Efficacy, tolerability,and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J. Cardiovasc. Pharmacol.38, 642–650 (2001).
   PubMed Web of Science ®Google Scholar
• Chiesi Farmaceutici S.p.A. Summary of product characteristics (Delaket 15 mg and 30 mg tablets) (2005).
   Google Scholar
• Ogihara T, Mikami H, Katahira K, Otsuka A. Comparative study of the effects of three angiotensin converting enzyme inhibitors on the cough reflex. Am. J. Hypertens.4(1 Pt 2), 46S–51S (1991).
   Google Scholar
• Fogari R, Malamani GD, Derosa G et al. Effect of delapril addition to manidipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. Am. J. Hypertens.16(5 Pt 2), 113A (2003).
   Web of Science ®Google Scholar
• Fogari R, Malamani GD, Zoppi A et al. Effect of benazepril addition to amlodipine on the ankle oedema and subcutaneous tissue pressure in hypertensive patients. J. Hum. Hypertens.17, 207–212 (2003).
   Google Scholar
• Trimarco B, Arcucci O, Gaciong Z et al. Evaluation of different combination of antihypertensive drugs in hypertensive patients not adequately controlled by previous monotherapy. High. Blood. Press. Cardiovasc. Prev.12(3), 180 (2005).
   Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey.JAMA283, 2404–2410 (2000).
   PubMed Web of Science ®Google Scholar
• Prisant LM, Weir MR, Papademetriou V et al. Low-dose combination therapy: an alternative first-line approach to hypertension treatment. Am. Heart J.130, 359–366 (1995).
   PubMed Web of Science ®Google Scholar
• Messerli FH. Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. Am. J. Hypertens.12(8 Pt 2), 86S–90S (1999).
   Google Scholar
• Ram C. Getting to goal in complex patients. Clin. Cardiol.26(Suppl II), 3–6 (2003).
   Google Scholar